Soros Robert Form 4 February 24, 2010

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

OMB APPROVAL

response...

if no longer subject to Section 16. Form 4 or Form 5

Check this box

obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

2. Issuer Name and Ticker or Trading

1(b).

FLOOR

(Print or Type Responses)

1. Name and Address of Reporting Person * SOROS FUND MANAGEMENT LLC

888 SEVENTH AVENUE, 31ST

(Last) (First)

(Middle)

3. Date of Earliest Transaction (Month/Day/Year)

02/22/2010

Symbol

5. Relationship of Reporting Person(s) to Issuer MAP Pharmaceuticals, Inc. [MAPP]

(Check all applicable)

Director Officer (give title below)

10% Owner Other (specify

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

3.

Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting

6. Individual or Joint/Group Filing(Check

NEW YORK, NY 10106

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of 2. Transaction Date 2A. Deemed Security (Month/Day/Year) Execution Date, if (Instr. 3) any

(Month/Day/Year)

TransactionAcquired (A) or Code Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5)

4. Securities

5. Amount of Securities Beneficially Owned Following Reported

6. Ownership 7. Nature of Form: Direct Indirect (D) or Indirect (I) (Instr. 4)

Beneficial Ownership (Instr. 4)

Transaction(s) (Instr. 3 and 4)

Common 02/22/2010 Stock

V J

Amount 706

<u>(2)</u> 3,135,172 Α

Price

(A)

or

(D)

I (1) (2) (3)

See **Footnotes**

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

(1)(2)(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: Soros Robert - Form 4

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5.	6. Date Exerc	cisable and	7. Title	e and	8. Price of	9. Nu
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	orNumber	Expiration D	ate	Amou	nt of	Derivative	Deriv
Security	or Exercise		any	Code	of	(Month/Day/	Year)	Under	lying	Security	Secui
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Derivative	e		Securi	ties	(Instr. 5)	Bene
	Derivative				Securities			(Instr.	3 and 4)		Own
	Security				Acquired						Follo
	·				(A) or						Repo
					Disposed						Trans
					of (D)						(Instr
					(Instr. 3,						
					4, and 5)						
									A		
									Amount		
						Date	Expiration		or		
						Exercisable	Date	Title	Number		
				~					of		
				Code V	(A) (D)				Shares		

Reporting Owners

/s/ Jodye M.

Anzalotta (6)

Reporting Owne	Relationships					
		Director	10% Owner	Officer	Other	
SOROS FUND MAN 888 SEVENTH AVE 31ST FLOOR NEW YORK, NY 10		X				
SOROS GEORGE 888 SEVENTH AVE 31ST FLR NEW YORK, NY 101	X					
Soros Robert C/O SOROS FUND M 888 SEVENTH AVE NEW YORK, NY 101		X				
SOROS JONATHAN C/O SOROS FUND M 888 SEVENTH AVE NEW YORK, NY 101		X				
Signatures						
/s/ Jodye M. Anzalotta (4)	02/24/2010					
**Signature of Reporting Person	Date					
/s/ Jodye M. Anzalotta (5)	02/24/2010					
**Signature of Reporting Person	Date					

02/24/2010

Reporting Owners 2 Edgar Filing: Soros Robert - Form 4

**Signature of Reporting

Person

Date

/s/ Jodye M. 02/24/2010 Anzalotta (7)

**Signature of Reporting Date

Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
 - All of the securities reported herein are held for the account of Perseus-Soros BioPharmaceutical Fund, LP ("Perseus-Soros"),
- (1) Perseus-Soros Partners, LLC ("Perseus-Soros Partners"), the general partner of Perseus-Soros, SFM Participation, L.P ("SFM Participation"), a managing member of Perseus-Soros Partners, Biotech Management Partners, LLC ("Biotech Management Partners") and Quantum Industrial Partners LDC ("QIP").
 - On February 22, 2010, Perseus 2000 Biotech Satellite, LLC distributed shares of the Issuers Common Stock pro rata to its partners for no consideration (the "Distribution"). In the Distribution, QIP received 706 shares of the Issuer's common stock. After the Distribution,
- (2) Perseus-Soros Partners holds 5,293 shares of the Issuers Common Stock, SFM Participation holds 10,410 shares of the Issuers Common Stock, Biotech Management Partners, LLC holds 23,933 shares of the Issuers Common Stock, QIP now holds 269,367 shares of the Issuers Common Stock and Perseus-Soros holds 2,826,169 shares of the Issuers Common Stock.
 - SFM Participation is a managing member of Biotech Management Partners. SFM AH, LLC, a Delaware limited liability company ("SFM AH"), is the general partner of SFM Participation. The sole managing member of SFM AH is SFM LLC. SFM LLC also serves as the
- (3) principal investment manager to QIP. Mr. George Soros ("Mr. Soros") serves as Chairman of SFM LLC, Mr. Robert Soros ("Robert Soros") serves as Deputy Chairman of SFM LLC and Mr. Jonathan Soros ("Jonathan Soros") serves as President and Deputy Chairman of SFM LLC.

Remarks:

- (4) Jodye M. Anzalotta is signing in her capacity as Ass't General Counsel of Soros Fund Management LLC.
- (5) Jodye M. Anzalotta is signing in her capacity as Attorney-in-Fact for Mr. George Soros.
- (6) Jodye M. Anzalotta is signing in her capacity as Attorney-in-Fact for Mr. Robert Soros.
- (7) Jodye M. Anzalotta is signing in her capacity as Attorney-in-Fact for Mr. Jonathan Soros.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3